Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) and other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection: No software was used

Data analysis: No software was used

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data are not publicly available due to them containing information that could compromise research participant privacy.

Field-specific reporting
**Life sciences study design**

All studies must disclose on these points even when the disclosure is negative.

| Sample size | Describe how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data exclusions | Describe any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established. |
| Replication | Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why. |
| Randomization | Describe how samples/organisms/participants were allocated into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why. |
| Blinding | Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study. |

**Behavioural & social sciences study design**

All studies must disclose on these points even when the disclosure is negative.

| Study description | This is a qualitative study exploring the perceptions of healthcare providers on the provision of recommended asthma care in Malaysia. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Research sample | 26 healthcare providers (5 medical officers, 4 nurses, 4 pharmacists, 4 medical assistants, 4 assistant pharmacists, 5 family medicine specialists) from 6 public primary care clinics in a semi-urban district of Malaysia. The findings might not be representative of centres elsewhere (e.g clinic from rural area) in Malaysia and challenges faced by the private general practitioners. We included all category of HCPs who were directly involved in asthma care in public primary care clinics in the study. This had provided a better understanding regarding the challenges faced by the HCPs at primary care level. Breakdown of sample demographics are: Medical officers: 5 female; age 28-39 years old; duration of practice: 3-13 years Nurses: 4 female; age 27-40 years old; duration of practice 4-17 years Pharmacists: 3 female, 1 male; age 26-32 years old; duration of practice 2-9 years Medical assistants: 4 male; age 27-35 years old; duration of practice 2-8 years Assistant pharmacists: 4 female; age 37-53 years old; duration of practice 10-25 years Family medicine specialists: 5 female; age 41-52 years old; duration of practice 17-26 years |
| Sampling strategy | We purposively sampled HCPs who had clinical involvement in asthma management i.e family medicine specialists, medical officers, medical assistants, nurses, pharmacists and assistant pharmacists. Data collection and analyses were performed in an iterative manner until no further new themes emerged. Recruitment was stopped after six focus group discussion when researchers agreed that the analysis had reached thematic saturation. |
| Data collection | We obtained contact information of HCPs involved in the management of patients with asthma from the Family Medicine Specialists in charge of the six public primary care clinics. Potential participants were approached via telephone call, text messages or email and invited to participate in the study. The purpose of the study was explained to the HCPs and a participant information sheet was sent to them to understand the study. For those who agreed to participate in the study, an appointment was made for a focus group discussion at which written consent was obtained. Prior to the group discussion, participants completed a sociodemographic questionnaire that provided the context for the data analysis. Focus groups were held in the six clinics or meeting rooms in the district health office. A semi-structured interview guide (Appendix 1), informed by literature on implementing guidelines was used to assist and facilitate discussion about participants’ experiences of management and challenges faced in delivering asthma care. Opinions were explored without restriction from the guide. Each session was moderated by a researcher (ATC, SSG or PYL) with the help of a note taker. All sessions were audio-taped with a voice recorder with consent. |
| Timing | July to August 2019 |
| Data exclusions | No data were excluded from analysis. |
| Non-participation | No participants dropped out/declined participation. |
| Randomization | Randomization is not relevant to our study as it is a qualitative study. |
Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Study description | Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Research sample  | Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source. |
| Sampling strategy | Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. |
| Data collection   | Describe the data collection procedure, including who recorded the data and how. |
| Timing and spatial scale | Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken. |
| Data exclusions   | If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established. |
| Reproducibility  | Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful. |
| Randomization    | Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why. |
| Blinding         | Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study. |

Did the study involve field work?  [ ] Yes  [ ] No

Field work, collection and transport

| Field conditions | Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall). |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Location         | State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth). |
| Access & import/export | Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information). |
| Disturbance      | Describe any disturbance caused by the study and how it was minimized. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a  | Involved in the study |
|------|-----------------------|
| [ ]  | Antibodies            |
| [x]  | Eukaryotic cell lines |
| [x]  | Palaeontology and archaeology |
| [x]  | Animals and other organisms |
| [x]  | Human research participants |
| [x]  | Clinical data         |
| [x]  | Dual use research of concern |

Methods

| n/a  | Involved in the study |
|------|-----------------------|
| [x]  | ChIP-seq              |
| [x]  | Flow cytometry        |
| [x]  | MRI-based neuroimaging |
### Antibodies

**Antibodies used**

Describe all antibodies used in the study, as applicable, provide supplier name, catalog number, clone name, and lot number.

**Validation**

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer’s website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

### Eukaryotic cell lines

**Policy information about cell lines**

**Cell line source(s)**

State the source of each cell line used.

**Authentication**

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

**Mycoplasma contamination**

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

**Commonly misidentified lines**

(See ICLAC register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

### Palaeontology and Archaeology

**Specimen provenance**

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

**Specimen deposition**

Indicate where the specimens have been deposited to permit free access by other researchers.

**Dating methods**

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

**Ethics oversight**

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Animals and other organisms

**Policy information about studies involving animals**

ARRIVE guidelines recommended for reporting animal research

**Laboratory animals**

For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

**Wild animals**

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

**Field-collected samples**

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

**Ethics oversight**

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Human research participants

**Policy information about studies involving human research participants**

**Population characteristics**

26 healthcare providers (5 medical officers, 4 nurses, 4 pharmacists, 4 medical assistants, 4 assistant pharmacists, 5 family medicine specialists) from 6 primary care clinics.

Medical officers: 5 female; age 28-39 years old; duration of practice: 3-13 years

Nurses: 4 female; age 27-40 years old; duration of practice 4-17 years

Pharmacists: 3 female, 1 male; age 26-32 years old; duration of practice 2-9 years

Medical assistants: 4 male; age 27-35 years old; duration of practice 2-8 years

Assistant pharmacists: 4 female; age 37-53 years old; duration of practice 10-25 years

Family medicine specialists: 5 female; age 41-52 years old; duration of practice 17-26 years
Recruitment

Contact information of HCPs involved in the management of patients with asthma were obtained from the Family Medicine Specialists in charge of the six public primary care clinics. Potential participants were approached via telephone call, text messages or email and invited to participate in the study. Recruitment was stopped after six focus group discussions were conducted when researchers agreed that the analysis had reached thematic saturation.

Ethics oversight

This study received ethical approval from the Medical Research and Ethics Committee of the Ministry of Health, Malaysia (NMRR ID: NMRR-18-2683-43494) and sponsorship approval from the Academic and Clinical Central Office for Research & Development (ACCORD) at the University of Edinburgh. All participants provided written informed consent.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol

Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

Dual use research of concern

Policy information about dual use research of concern

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No

Public health

National security

Crops and/or livestock

Ecosystems

Any other significant area

Yes

Experiments of concern

Does the work involve any of these experiments of concern:

No

Demonstrate how to render a vaccine ineffective

Confer resistance to therapeutically useful antibiotics or antiviral agents

Enhance the virulence of a pathogen or render a non-pathogen virulent

Increase transmissibility of a pathogen

Alter the host range of a pathogen

Enable evasion of diagnostic/detection modalities

Enable the weaponization of a biological agent or toxin

Any other potentially harmful combination of experiments and agents

Yes

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.
Provide a link to an anonymized genome browser session for “Initial submission” and “Revised version” documents only, to enable peer review. Write “no longer applicable” for “Final submission” documents.

**Methodology**

| Replicates | Describe the experimental replicates, specifying number, type and replicate agreement. |
|------------|-------------------------------------------------------------------------------------|
| Sequencing depth | Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end. |
| Antibodies | Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number. |
| Peak calling parameters | Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used. |
| Data quality | Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment. |
| Software | Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details. |

**Flow Cytometry**

| Plots | Confirm that: |
|-------|---------------|
| | The axis labels state the marker and fluorochrome used (e.g. CD4-FITC). |
| | The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ’group’ is an analysis of identical markers). |
| | All plots are contour plots with outliers or pseudocolor plots. |
| | A numerical value for number of cells or percentage (with statistics) is provided. |
| Methodology | Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used. |
| Instrument | Identify the instrument used for data collection, specifying make and model number. |
| Software | Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details. |
| Cell population abundance | Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined. |
| Gating strategy | Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between “positive” and “negative” staining cell populations are defined. |
| | Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. |

**Magnetic resonance imaging**

| Experimental design | Indicate task or resting state; event-related or block design. |
|---------------------|---------------------------------------------------------------|
| Design specifications | Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials. |
| Behavioral performance measures | State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects). |
### Acquisition

| Imaging type(s) | Specify: functional, structural, diffusion, perfusion. |
|----------------|-----------------------------------------------------|
| Field strength | Specify in Tesla                                      |
| Sequence & imaging parameters | Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle. |
| Area of acquisition | State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined. |
| Diffusion MRI | □ Used □ Not used |

### Preprocessing

| Preprocessing software | Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.). |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Normalization          | If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization. |
| Normalization template | Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI/305, ICBM152) OR indicate that the data were not normalized. |
| Noise and artifact removal | Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration). |
| Volume censoring       | Define your software and/or method and criteria for volume censoring, and state the extent of such censoring. |

### Statistical modeling & inference

| Model type and settings | Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation). |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect(s) tested        | Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used. |
| Specify type of analysis: | □ Whole brain □ ROI-based □ Both |
| Statistic type for inference | (See Fink et al. 2016) Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods. |
| Correction              | Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo). |

### Models & analysis

| n/a | Involved in the study |
|-----|-----------------------|
|     | □ □ Functional and/or effective connectivity |
|     | □ □ Graph analysis |
|     | □ □ Multivariate modeling or predictive analysis |

| Functional and/or effective connectivity | Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information). |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Graph analysis                          | Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.). |
| Multivariate modeling and predictive analysis | Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics. |